<DOC>
	<DOCNO>NCT02459288</DOCNO>
	<brief_summary>A 4 week-duration cross-over study Ticagrelor Clopidogrel Acute Coronary Syndrome ( ACS ) Chronic Kidney Disease ( CKD ) subject , focus platelet inhibition safety observation .</brief_summary>
	<brief_title>Platelet Resistance With Ticagrelor Standard-Dose Clopidogrel Among CKD ACS Patients</brief_title>
	<detailed_description>Acute coronary syndrome high mortality costly disease . Antiplatelet therapy , include aspirin P2Y12 antagonist , play important role acute subacute stage treatment acute coronary syndrome , especially coronary stent implantation . Patients decrease estimate glomerular filtration rate ( eGFR ) experience high cardiovascular morbidity mortality . Clopidogrel , one P2Y12 receptor antagonist , inhibits receptor 's activation block interaction ADP . However , efficacy clopidogrel show substantial variation residual platelet reactivity , related adverse cardiovascular outcome , especially impaired renal function . Our study aim check platelet inhibition rate compare medication cross-over study among CKD subject ACS condition .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Female male , age 2075 year 3 . Stage 35 chronic kidney disease ( eGFR &lt; 60ml/min ) patient ESRD 4 . Taking standard treatment dose clopidogrel ( 75mg/day ) 1 week 5 . Patients eligible enrollment hospitalize acute coronary syndrome , without STsegment elevation , onset symptom past 6 month . 6 . For patient acute coronary syndrome without STsegment elevation , least two follow three criterion meet : STsegment change electrocardiography , indicate ischemia ; positive test biomarker , indicate myocardial necrosis ; one several risk factor ( age ≥60 year ; previous myocardial infarction coronaryartery bypass graft [ CABG ] ; coronary artery disease stenosis ≥50 % least two vessel ; previous ischemic stroke , transient ischemic attack , carotid stenosis least 50 % , cerebral revascularization ; diabetes mellitus ; peripheral arterial disease ) . 7 . For patient acute coronary syndrome STsegment elevation , follow two inclusion criterion meet : persistent STsegment elevation least 0.1 mV least two contiguous lead new left bundlebranch block . 1 . Oral anticoagulation therapy stop 2 . Increased risk bradycardia 3 . Concomitant use strong CYP3A inhibitor/inducers 4 . Unwilling sign inform consent 5 . Allergic contraindicate study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>eGFR</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>